Cargando…

P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.

Detalles Bibliográficos
Autores principales:	Dickinson, Michael, Berkahn, Leanne, Trotman, Judith, Butler, Jason, Neeson, Paul, Bressel, Matthias, Minson, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431515/ http://dx.doi.org/10.1097/01.HS9.0000971160.69126.7e

Ejemplares similares

Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy
por: Taenaka, Ryutaro, et al.
Publicado: (2022)

1066 Delay in the Norwegian Immunisation Programme
por: Riise, Oystein
Publicado: (2014)

A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma
por: Yonezawa, Ryo, et al.
Publicado: (2023)

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
por: Grivas, Petros, et al.
Publicado: (2020)

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
por: Gibb, A, et al.
Publicado: (2013)

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
por: Radford, John, et al.
Publicado: (2022)

Closing Symposium of the DFG Research Unit FOR 1066
por: Radespiel, Rolf, et al.
Publicado: (2016)

The four orchestral suites, BWV 1066-1069 /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (2000)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

4 Ouvertüren, BWV 1066-1069 Suites ; Ouvertüre BWV 1070 /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1986)

English society in the early middle ages, (1066-1307) /
por: Stenton, Doris Mary
Publicado: (1981)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Deliverance
por: Dickey, James
Publicado: (1970)

1066 and all that : A memorable history of England, comprising all the parts you can remember, including 103 Good things, 5 bad Kings, and 2 Genuine Dates
por: Sellar, Walter Carruthers
Publicado: (1960)

Notification Strategy and Predictors of Outcome in Stroke Ineligible for Reperfusion Therapies
por: Mirolovics, Ágnes, et al.
Publicado: (2019)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting
por: Uchida, Mayako, et al.
Publicado: (2018)

1066. Antimicrobial Stewardship Program: Audit and Feedback for Continued Improvement
por: Wang, Joseph, et al.
Publicado: (2019)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

The Deliverances of the Retina
por: Blackham, Geo. E.
Publicado: (1882)

The Deliverances of the Retina
por: Abbott, F. W.
Publicado: (1882)

P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY
por: Minson, Adrian, et al.
Publicado: (2023)

The attitudes of 1066 patients with cancer towards participation in randomised clinical trials
por: Jenkins, V, et al.
Publicado: (2010)

Sustained remission after ABVD treatment for interdigitating dendritic cell sarcoma
por: Helbig, Grzegorz, et al.
Publicado: (2014)

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma
por: Amin, M. S. A., et al.
Publicado: (2020)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy
por: Zhu, Dingliang, et al.
Publicado: (2014)

Precluding rare outcomes by predicting their absence
por: Schoon, Eric W., et al.
Publicado: (2019)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

RF multipoles deliverable
por: Cruz Alaniz, Emilia, et al.
Publicado: (2020)

Fabian Deliverances on Sanatoria
Publicado: (1913)

Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report
por: Gangopadhyay, Aparna, et al.
Publicado: (2012)

M10.6.6: Designed and manufactured Frequency Synthesizer Board (AMC)
por: Czuba, K
Publicado: (2011)

Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line
por: Wang, Yemin, et al.
Publicado: (2020)

1066. In Vitro and in Vivo Antimicrobial Activity of Cefiderocol and Comparators against Achromobacter spp
por: Nakai, Ryuichiro, et al.
Publicado: (2021)

Factors associated with complications after percutaneous nephrolithotomy: an analysis of 1,066 cases
por: Said, Danniel Frade, et al.
Publicado: (2023)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies
por: Pettit, Kristen, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_565ptnvg8dp8qtbopaki59idiu